[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351335-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351335-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ancestrally-diverse-autologous-patient-derived-organoidimmune-cell-coculture-platform-for-addressing-immunotherapeutic-outcome-disparities-in-high-grade-endometrial-cancer","Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer","","High-grade endometrial cancers disproportionately affect women of African ancestry and often resist available immunotherapies. Mechanistic study is limited by preclinical models that fail to preserve ancestral diversity and patient-matched tumor–immune interactions without confounding alloreactivity. An autologous platform was built using 85 diverse patient-derived organoids paired with autologous immune cells and real-time live imaging. HGECs show reduced MHC class I and II antigen presentation, reversed by IFNγ or EZH2 inhibition, sensitizing organoids to autologous cytotoxicity, including enhanced NK killing and stronger engagement in MMR-deficient tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ancestrally-diverse-autologous-patient-derived-organoidimmune-cell-coculture-platform-for-addressing-immunotherapeutic-outcome-disparities-in-high-grade-endometrial-cancer/351335/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ancestrally-diverse-autologous-patient-derived-organoidimmune-cell-coculture-platform-for-addressing-immunotherapeutic-outcome-disparities-in-high-grade-endometrial-cancer/351335.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are existing preclinical models insufficient for high-grade endometrial cancer immunotherapy research?","Question",{"text":63,"@type":64},"They often do not preserve ancestral diversity and patient-matched tumor–immune interactions, and may introduce confounding effects related to alloreactivity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the organoid–immune coculture platform characterize immune evasion in HGEC?",{"text":68,"@type":64},"It uses real-time live-imaging readouts to show that HGECs suppress MHC class I and II antigen presentation pathways compared with matched normal counterparts.",{"name":70,"@type":61,"acceptedAnswer":71},"What interventions restored antigen presentation and improved immune killing in HGEC organoids?",{"text":72,"@type":64},"Antigen presentation was restored by IFNγ stimulation or by epigenetic reprogramming through EZH2 inhibition, which sensitized HGEC organoids to autologous T cell–mediated cytotoxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351335,1790155996,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0193](https://doi.org/10.1158/2767-9764.CRC-25-0193)  OPEN ACCESS  \nAncestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer  \nCharlie Chung1,2, Brian Yueh1, Santhilal Subhash1, Onur Eskiocak1,2, Aaron Nizam1,3, Marissa Viola4, Pascal Belleau1, Ariel Kredentser1,3, Arisa Kapedani3, Alexander Krasnitz1, Ken Simon4, Werner Meier4, Marina Frimer3,5, Gary L. Goldberg3,5, and Semir Beyaz1  \n􀀶  \nABSTRACT  \nHigh-grade endometrial cancers (HGEC) disproportionately affect women of African ancestry and often resist currently available immunotherapies. Defining the mechanisms driving this resistance is impeded by a lack of preclinical models that preserve ancestral diversity and patient-matched tumor–immune interactions without confounding alloreactivity. To address this gap, we established a biobank of 85 endometrial cancer patientderived organoids (PDO) from a diverse cohort, enriched for HGEC PDOs from African American patients, and paired these with autologous immune cells to develop a patient-specific PDO–immune cell coculture platform with real-time live-imaging readouts. Using this system, we found that HGECs evade immune surveillance through pronounced suppression of major histocompatibility complex (MHC) class I and II antigen presentation pathways relative to their matched normal counterparts. Restoring antigen presentation, either by IFNγ stimulation or epigenetic reprogramming via enhancer of zeste homolog 2 inhibition, rescued MHC expression and sensitized HGEC PDOs to autologous T cell–mediated cytotoxicity. Extending the platform to NK cells revealed heightened killing of low–MHC-I PDOs. Consistent with clinical observations, mismatch  \nrepair (MMR)-deficient HGEC PDOs exhibited stronger immune engagement than their MMR-proficient counterparts. Finally, this platform enabled evaluation of the safety and efficacy of emerging immunotherapies, including protease-activatable bispecific T-cell engagers and EGFRtargeted chimeric antigen receptor T cells. Together, this sustainable, scalable, ancestrally diverse autologous PDO–immune cell coculture platform offers a robust resource for dissecting immune evasion mechanismsand accelerating the development of new immunotherapies to address disparities in endometrial cancer outcomes.  \nSignificance: The efficacy of immunotherapy for HGECs remains limited, partly because current preclinical models poorly capture tumor heterogeneity and patient-specific immune microenvironment. These cancers disproportionately affect women of African ancestry, yet most studies rely on European ancestry samples. We developed an autologous PDO and immune cell coculture platform from patients of diverse ancestries. This system enables patient-level analysis of tumor–immune interactions to support development and testing of novel immunotherapeutic strategies.  \nIntroduction  \nEndometrial cancer is the most common gynecologic malignancy and one of the leading causes of cancer-related morbidity and mortality among women  \n1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 2Department of Genetics, Stony Brook University, Stony Brook, New York. 3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwell Health, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York. 4Revitope Oncology, Concord, Massachusetts. 5Feinstein Institutes for Medical Research, Manhasset, New York.  \nCorresponding Author: Semir Beyaz, Cancer Center, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724. E-mail: [beyaz@cshl.edu](beyaz@cshl.edu)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-25-0193  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.  \n©2026 The Authors; Published by the ","cbCaieNA3hDjiAbs","https://ap.wps.com/l/cbCaieNA3hDjiAbs","pdf",42210396,15,"English","# Abstract\n## Significance\n# Introduction\n## Background on endometrial cancer types and disparities\n## Current treatment landscape and immunotherapy approvals","[{\"question\":\"Why are existing preclinical models insufficient for high-grade endometrial cancer immunotherapy research?\",\"answer\":\"They often do not preserve ancestral diversity and patient-matched tumor–immune interactions, and may introduce confounding effects related to alloreactivity.\"},{\"question\":\"How does the organoid–immune coculture platform characterize immune evasion in HGEC?\",\"answer\":\"It uses real-time live-imaging readouts to show that HGECs suppress MHC class I and II antigen presentation pathways compared with matched normal counterparts.\"},{\"question\":\"What interventions restored antigen presentation and improved immune killing in HGEC organoids?\",\"answer\":\"Antigen presentation was restored by IFNγ stimulation or by epigenetic reprogramming through EZH2 inhibition, which sensitized HGEC organoids to autologous T cell–mediated cytotoxicity.\"}]","Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer | PDF",1790093594,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3b768929c4e47a27a2c5f69f883bcf2.webp",983,1263,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2741532d8f1641a5e275df8883b5d09.webp",982,1262,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f6a20a211e3150c91076ee2673655ac.webp",981,1261,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22de088e2eaa399d43c0d7994d623779.webp",980,1259]